Liminal BioSciences gets Nasdaq notice on minimum bid price deficiency

Mar. 07, 2022 5:10 PM ETLMNLBy: Jessica Kuruthukulangara, SA News Editor1 Comment

Liminal BioSciences (NASDAQ:LMNL) received a written notice from the Nasdaq indicating that it is not in compliance with the minimum bid price requirement of $1/share.
In the event LMNL does not regain compliance by Aug. 31, the company may be eligible for additional time to regain compliance or may face delisting.
LMNL fully intends to resolve the deficiency and regain compliance with the listing rules.